Literature DB >> 15842389

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity--a rebuttal.

S Sallah, M Isaksen, S Seremetis, L Payne Rojkjaer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15842389     DOI： 10.1111/j.1538-7836.2005.01254.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  3 in total

Review 1.  Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.

Authors:  M Asif A Siddiqui; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007

Review 3.  Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.

Authors:  Geir E Tjønnfjord; Pål Andre Holme
Journal:  Vasc Health Risk Manag       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.